Protracted review period for Exubera
The FDA notified Pfizer and Sanofi-Aventis that it is extending the original review period for Exubera, the companies’ experimental inhaled ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Your message:
The e-mail address(es) that you supply to use this service will only be used to send the requested article.